Navigation Links
Watson Announces District Court Ruling in Naproxen Sodium Patent Suit
Date:8/13/2008

CORONA, Calif., Aug. 13 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that the United States District Court for the Southern District of Florida ruled today that Watson's Naproxen Sodium ER tablets, the generic version of Naprelan(R), infringes Elan's U.S. Patent No. 5,637,320 (the "'320 Patent"). The action, Elan Corporation Plc v. Andrx Pharmaceuticals, Inc., was initially brought by Elan in October 1998 following Andrx's filing of a paragraph IV Abbreviated New Drug Application for its product. In March 2002, the District Court ruled that Elan's '320 Patent was invalid. Subsequently, in May 2004, the United States Court of Appeals for the Federal Circuit reversed the District Court's finding of invalidity and remanded the case for further proceedings. In January 2005, Elan filed a related case against Andrx in the United States District Court for the Southern District of Florida alleging that Andrx's Naproxen Sodium ER tablets infringe the '320 Patent, and seeking damages for willful infringement. In late 2005 the parties completed briefing the District Court on the validity of the '320 Patent and whether Andrx's product infringes the '320 Patent. The matter has been under submission to the District Court since late 2005. In today's ruling, the District Court held that Andrx's Naproxen Sodium ER tablets infringe the '320 Patent and that Andrx's infringement was willful. The District Court has set a further hearing on the matter for September 19, 2008, to address issues related to a damages phase of the trial and the possibility of injunctive relief. The Company intends to appeal today's ruling.

"We are disappointed and disagree with the court's ruli
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
2. Watson Wyatt Identifies Major Benefit Trends During Open Enrollment Season
3. Texas Affiliates of Susan G. Komen for the Cure, Sen. Kirk Watson, Rep. Patrick Rose, Singer Kelly Willis, Breast Cancer Survivors and Activists Rally for Passage of Proposition 15
4. Watson Files FDA Application for Generic YAZ(R)
5. Watson Names Mark Durand Chief Financial Officer
6. Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation
7. Barr Subsidiary Sues Watson and Sandoz for SEASONALE(R) Patent Infringement
8. Watson Confirms Patent Litigation With Barr Related to Seasonale(R)
9. Watson Receives FDA Approval for Generic DuoNeb(R)
10. Watson to Distribute Alendronate Tablets
11. Medical Cost Increases to Accelerate Worldwide Over Next Five Years, Watson Wyatt Poll Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 04, 2015 Now in its ... clinical leaders who have made outstanding contributions to the ... serve, both in acute and post-acute care settings. The ... Post-Acute Provider of the Year, Advanced Practice Clinician of ... Provider of the Year. Recipients are selected by IPC’s ...
(Date:5/4/2015)... Washington, DC (PRWEB) May 04, 2015 ... of Kit Check as a finalist for the EY ... Washington Region. The awards program recognizes entrepreneurs who ... innovation, financial performance and personal commitment to their businesses ... finalist by a panel of independent judges. Award ...
(Date:5/4/2015)... CA (PRWEB) May 04, 2015 ... is now offering a more comfortable and attractive alternative ... restoration of choice for those who have lost teeth. ... can feel insecure or slip at the worst possible ... eats or talks. They can also painfully pinch or ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Ticket Down is ... the Colonial Life Arena in Columbia, South Carolina. ... continuation of his “Out There” tour which originally kicked off ... tour is North America and the legendary performer recently announced ... the Wells Fargo Arena on June 21st, in Charlottesville, VA ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 CCL, a ... offer this unique program to other leadership development consultancies. ... ties between CCL and successful practitioners, expanding our capacity ... the globe,” said John R. Ryan, CCL President and ... the CCL Partner Network , it will schedule ...
Breaking Medicine News(10 mins):Health News:IPC Healthcare Announces Clinicians of the Year 2Health News:IPC Healthcare Announces Clinicians of the Year 3Health News:EY announces Kit Check CEO and Co-founder Kevin MacDonald as an EY Entrepreneur Of The Year® 2015 Award finalist in the Greater Washington Region 2Health News:Los Angeles Dental Implants Doctor, Kevin Sands DDS, Now Offers a More Comfortable and Aesthetically-Pleasing Solution to Denture-Wearers 2Health News:Paul McCartney Tickets at Colonial Life Arena in Columbia, SC: Ticket Down Slashes Paul McCartney Ticket Prices in Columbia, South Carolina at Colonial Life Arena 2Health News:The Center for Creative Leadership Is Partnering with Lead Star to Create the CCL Partner Network 2
... surpass quarter million dollars, ANAHEIM, Calif., March 18 ... laptop computer carrying cases and,accessories is proud to announce ... in their battle against Breast Cancer. In their fourth,year ... percent of the,retail sales price of each Komen laptop ...
... (OTC Bulletin,Board: NTRZ), a world leader in stabilized rice bran ... step down from,his role as Chief Financial Officer on March ... role of Chief Financial Officer on that date.,Mr. Crow has ... smooth,transition of his responsibilities to Mr. Mueller., Mr. Mueller ...
... Kennedy, BABY MADNESS: MULTIPLES Offers Tips, from Celebrity Moms Kate Gosselin ... ... Baby Bloopers--, SILVER SPRING, Md., March 17 The signs ... basketball and of course, BABY MADNESS! Discovery Health,s second,annual television event ...
... space details Earths land cover with a resolution never before ... Organisation, presented the preliminary version of the map to scientists ... in Rome, Italy. , Earths land cover has been charted ... available to the public upon its completion in July, has ...
... Testing Requirements, VANCOUVER, March 17 /PRNewswire-FirstCall/ - ... the U.S. Food and Drug Administration (FDA),has completed ... (sNDA) for,Aczone(TM) and has removed the glucose-6-phosphate dehydrogenase ... extremely pleased to report the FDA decision to ...
... Care Center at ... Hospital, and Nyack Hospital, HACKENSACK, N.J., March 17 ... anticipated debut in The Kennedy Funding,Invitational for 2008, July 9-13. ... hospital breast care centers. Co-Directors,James Miller, Mitch Klein, and Kevin ...
Cached Medicine News:Health News:Mobile Edge Continues Fight Against Breast Cancer 2Health News:NutraCea Appoints New Chief Financial Officer 2Health News:NutraCea Appoints New Chief Financial Officer 3Health News:Baby Madness is Sweeping the Nation! Forty Sets of Twins and Triplets 'Hit the Court' in Discovery Health's BABY MADNESS: MULTIPLES 2Health News:New portrait of Earth shows land cover as never before 2Health News:QLT announces positive FDA action on Aczone(TM) 2Health News:QLT announces positive FDA action on Aczone(TM) 3Health News:Superstar John McEnroe to Highlight The Kennedy Funding Invitational Tennis Tournament, July 9-13, 2008 2Health News:Superstar John McEnroe to Highlight The Kennedy Funding Invitational Tennis Tournament, July 9-13, 2008 3Health News:Superstar John McEnroe to Highlight The Kennedy Funding Invitational Tennis Tournament, July 9-13, 2008 4
(Date:5/4/2015)... Calif. , May 4, 2015  Impax Laboratories, ... filled two key executive leadership roles, appointing  Donna M. ... Deborah M. Penza , as Senior Vice President, Chief ... report to Impax,s President and Chief Executive Officer, ... Donna and Deborah have joined the Impax team," said ...
(Date:5/4/2015)... -- Bayer HealthCare (Bayer) has entered into an exclusive ... ) on ISIS-FXI Rx, an antisense investigational drug ... the agreement Bayer will further develop and commercialize ISIS-FXI ... As part of the clinical development program, Bayer plans ... in an appropriate patient community. "Bayer is ...
(Date:5/4/2015)... ANGELES , May 4, 2015  CytRx ... and development company specializing in oncology, today announced ... 1b aldoxorubicin combination studies pairing aldoxorubicin with either ... of gemcitabine or ifosfamide with escalating doses of ... and even at the lowest dose level of ...
Breaking Medicine Technology:Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 2Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 3Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 2CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 4CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 5CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 6CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 7
... ZymoGenetics,Inc. today announced that interim findings were presented ... B-cell chronic,lymphocytic leukemia (B-CLL) at the American Society ... included intravenous,administration of higher doses than had been ... was well-tolerated and biologically,active at all dose levels ...
... Biotechnology,Inc. (OTCBB: CGRB) today announced that positive interim ... prostate cancer drug candidate,CB7630 (abiraterone acetate) was presented ... Meeting, which is currently,taking place in Chicago, Illinois. ... Saturday, June 2nd, as part of the poster,discussion ...
Cached Medicine Technology:ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia 2ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia 3Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ASCO Annual Meeting 2Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ASCO Annual Meeting 3Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ASCO Annual Meeting 4Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ASCO Annual Meeting 5Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ASCO Annual Meeting 6